HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PRE
Prenetics Global Limited
PRE lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PRE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Weak |
PRE's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PRE PE Valuation
PRE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
PRE has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PRE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.16 | -$0.29 |
| Q1 2026 | -$4.58 | -$0.77 |
| Q4 2025 | -$4.02 | -$0.31 |
| Q3 2025 | -$3.56 | +$0.26 |
| Q2 2025 | -$3.87 | +$0.27 |
| Q1 2025 | -$3.81 | +$1.51 |
| Q4 2024 | -$3.71 | +$1.90 |
| Q3 2024 | -$3.82 | +$0.24 |
PRE has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over PRE on profitability, with a higher operating margin.
PRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $46.5M | +163% |
| Q1 2026 | $36M | +108% |
| Q4 2025 | $36.6M | +249% |
| Q3 2025 | $23.6M | +203% |
| Q2 2025 | $17.7M | +198% |
| Q1 2025 | $17.3M | +170% |
| Q4 2024 | $10.5M | +99% |
| Q3 2024 | $7.8M | +59% |
PRE has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -47% | +9.8 points |
| Q1 2026 | -27% | +34 points |
| Q4 2025 | -34% | +124 points |
| Q3 2025 | -26% | +126 points |
| Q2 2025 | -57% | +122 points |
| Q1 2025 | -61% | +81 points |
| Q4 2024 | -158% | +59 points |
| Q3 2024 | -152% | +114 points |
PRE's operating margin was −47% last quarter, up 9.8 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PRE on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | -$12.1M | -$12.1M |
| Q4 2025 | -$22M | -$22M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PRE's free cash flow was −$34M over the past year, against $0 the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PRE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.7% | +284K shares |
| 1 year | +30% | +4M shares |
| 3 years | +63% | +6.7M shares |
| 5 years | +561% | +14.7M shares |
PRE has 17M diluted shares, up 30% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $26.9M |
| Q1 2026 | $13.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PRE spent $40M buying back its own shares over the past year, after none the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PRE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 50.8x | High |
| Q1 2021 | 2.2x | Moderate |
| Q4 2020 | 0.5x | Very low |
PRE's net debt is more than 20 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.2 | Neutral |
| Stochastic | 13.9 | Oversold |
PRE's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PRE PE vs Healthcare Sector
PRE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.9 | 12% below |
| 20 week MA | $19.9 | 16% below |
| 50 week MA | $18.8 | 11% below |
| 100 week MA | $13.4 | 24% above |
| 200 week MA | $10.7 | 56% above |
PRE has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $120.6 | $31.5 | -74% |
| 2023 | $31.5 | $5.91 | -81% |
| 2024 | $5.91 | $5.70 | -3.6% |
| 2025 | $5.70 | $16.9 | +196% |
| 2026 YTD | $16.9 | $16.7 | -0.9% |
PRE has the edge over HIMS on returns for 2026, with the stronger performance.